Bio-Rad Laboratories, Inc. (BIO)
- Previous Close
231.57 - Open
235.66 - Bid --
- Ask --
- Day's Range
229.84 - 236.15 - 52 Week Range
215.38 - 387.99 - Volume
280,579 - Avg. Volume
388,045 - Market Cap (intraday)
6.338B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-76.53 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
318.67
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
www.bio-rad.comRecent News: BIO
View MorePerformance Overview: BIO
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIO
View MoreValuation Measures
Market Cap
6.34B
Enterprise Value
6.05B
Trailing P/E
--
Forward P/E
29.85
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.57
Price/Book (mrq)
0.95
Enterprise Value/Revenue
2.38
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-85.16%
Return on Assets (ttm)
1.55%
Return on Equity (ttm)
-27.52%
Revenue (ttm)
2.54B
Net Income Avi to Common (ttm)
-2.16B
Diluted EPS (ttm)
-76.53
Balance Sheet and Cash Flow
Total Cash (mrq)
1.66B
Total Debt/Equity (mrq)
20.50%
Levered Free Cash Flow (ttm)
250.23M